P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (R/R NHL). (23rd June 2022) - Hernandez-Ilizaliturri, F. J.; Kuruvilla, J.; Christian, B. A.; Flinn, I. W.; Assouline, S. E.; Ulrickson, M. L.; Landsburg, D. J.; Stuart, M.; Lowman, H.; Levin, N.; Maetzel, D.; Viller, N. N.; et al.